CompletedNot Applicable

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

United States23 participantsStarted 2015-11-16

Plain-language summary

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>/= 18 years * Initiating cabozantinib for progressive DTC, MTC, malignant PH or PGs or lenvatinib for progressive DTC or MTC as determined by patient's endocrinologist * ECOG performance status 0-2 * Able to communicate in English or Spanish * Able to provide informed consent Exclusion Criteria: * Active participation in any weight reduction program including use of drugs used for weight loss * Inability to ambulate without assistance (e.g. cane, walker) * Multiple Endocrine Neoplasia (MEN) 2B (due to differences in body habitus) * Patients unwilling or unable to comply with the protocol. * Use of chronic (\>3 months consecutively) non-physiological (15 mg/m² hydrocortisone equivalent) doses of glucocorticoids * Non-English speaking PH and PG patients

What they're measuring

Change in weight among patients who have no gastrointestinal (GI) adverse events (AEs) or have =< grade 1 symptoms and those with grade 2 or above AEs, according to the National Cancer Institute Common Toxicity Criteria version 4.0

Timeframe: Baseline to up to 6 months

Trial details

NCT IDNCT02592356

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Differentiated Thyroid Gland Carcinoma trials